Merck gets USFDA nod for KEYTRUDA as adjuvant treatment for non-small cell lung cancer Ruchika Sharma30 Jan 2023 9:15 AMKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
USFDA grants accelerated approval for Mirati Therapeutics lung cancer drug KRAZATI Ruchika Sharma13 Dec 2022 10:00 AMSan Diego: Mirati Therapeutics, Inc., a targeted oncology company, has announced that the U.S. Food and Drug Administration (USFDA) has granted...
Europe recommends lung cancer drugs from AstraZeneca, Lilly savita thakur thakur19 Dec 2015 6:11 AMThe European Medicines Agency said its experts had recommended marketing approval for lung cancer drugs developed by AstraZeneca and Eli Lilly and...
